TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: caregiver-assessed pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically detected parastomal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to relapse or recurrence
Endpoint domain: Mortality/survival
Primary endpoint: mean post-operative time interval to bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean intravenous fluid required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of systemic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: mean blood flow velocity in the left MCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute power density < 4 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence rates of grade 2 or more nausea
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rates of grade 2 or more anorexia
Endpoint domain: Adverse events/effects
Primary endpoint: Claudication Onset Time (COT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Walking Time (PWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic AF/AFL recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of surgical wound infection at discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of alpha‐linolenic acid and eicosapentaenoic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Release of prostaglandin E(1) and leukotriene B(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of prostaglandin E(2) and interleukin‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect site concentration (Ce50) of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure vs estimated energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in plasma iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in serum bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum 25‐hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality within 90 days after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patients receiving postoperative chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily pain-related catastrophizing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean binocular distance best spectacle‐corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of dysphotopsia phenomena
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective rating of pain (VAS-scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual flap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual tissue ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom reduction in perceived stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISGA score success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduced aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased prosocial behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved academic engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Knowledge about contraceptive effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraocular pressure (IOP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: negative peak latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Closure of PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Support for mobilization in critically ill children
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kaplan-Meier predicted exit percentage at day 112
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Global Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Global Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of early postoperative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity of at least 20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MP on the Symbol Digit Modalities Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial thigh sensory loss
Endpoint domain: Adverse events/effects
Primary endpoint: HSV‐2 seroconversions
Endpoint domain: Mortality/survival
Primary endpoint: Plasma acetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breath acetaldehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal function (serum creatinine and estimated glomerular filtration rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total serum bile acid pool expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4 density on T-lymphocyte surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: average tattoo fading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of tattoos with >50% fading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of tattoos with >75% fading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHOICE adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C targets achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CushingQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive and motor deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Verbal short-term memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: BMI SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parasitological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative conjunctival chemosis
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal stromal hydration requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores during extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacoadherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum resistin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-cholesterol control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic improvement rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rating score for surgical conditions while suturing the hernia defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: grade of effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acceptable quality of preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Identification of confirmed cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute management offered to identified victims
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NV area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of leakage from NVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous Vaginal Birth (SVB) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to deterioration for cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to deterioration for dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endothelial Dysfunction Velocity (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maternal temperature elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Global Assessment of Functioning Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in facial skin appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in hair thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in hair breakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: plasma SPM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device
Endpoint domain: Mortality/survival
Primary endpoint: subject's acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality of preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of Life (QoL) - total SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Role limitations due to emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: protein and cell accumulation in the alveolar space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evans Blue dye extravasation into the lung parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: biochemical parameters of high tidal volume‐induced tissue oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variance in tumor measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Meconium Aspiration Syndrome (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of other respiratory disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complications of intubation
Endpoint domain: Adverse events/effects
Primary endpoint: polymorphonuclear leukocytes on a vaginal wall smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Early hepatic encephalopathy rates
Endpoint domain: Adverse events/effects
Primary endpoint: rate of positive urine cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bath AS disease activity index (BASDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bath AS function index (BASFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for cavity preparation technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: µSBS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New brain ischaemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Physical Activity Energy Expenditure (PAEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for stavudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-8h for stavudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phoneme awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reading skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endurance capacity test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V·O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain VAS improvement at first week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal CVC during PORH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall score on the Mattis dementia rating scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of ink removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-wave phase shifts between CBFV and blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: B-wave phase relation between blood pressure and CBFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient's response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: fasting plasma triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: very low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative survival and success rates for implants
Endpoint domain: Mortality/survival
Primary endpoint: Patient Esthetic Score (PES)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: visual numeric pain scale values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for opioid rescue postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of nausea/vomiting postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: motor block time prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medio‐Lateral Stability Index (MLSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ZDS score reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in tumour size and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall good histopathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Procedure interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma-related patient-reported outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postprandial glucose excursion (AUC-15-240 min-glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose variability (SD-15-240 min-glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GLP-1 secretion (AUC-15-240 min-GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients who successfully awaken within 14 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rectal temperature change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful abortions
Endpoint domain: Mortality/survival
Primary endpoint: Vomiting and fever/chills
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in major coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Gingival Index (GI) score > or =2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of unprotected anal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lost work performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Need for joint replacement surgery
Endpoint domain: Mortality/survival
Primary endpoint: score of logical memory test‐I and II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total score of digit span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30 min delayed‐recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence rate of hydatid liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of viable cysts at the time of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of cancer growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in pain (WOMAC pain subscale scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymph node count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cases with <12 lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Skeletal muscle mass (SMM) gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relative strength increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-rated distress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol levels at awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: efficiency of nasal mucosa transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesic demand
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative pain (VAS value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing complications
Endpoint domain: Adverse events/effects